{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'NEUTROPENIA', 'Neutrophils V 1000/mm\u00b3', 'Repeat immediately a full blood count if value close', 'to 1000/mm3', 'Neutrophils < 1000/mm\u00b3 confirmed', 'Neutrophils Y 1000/mm\u00b3 confirmed', 'with signs of infection', 'with no signs of infection', '1. DISCONTINUE', '1. DISCONTINUE', 'Investigational Product,', 'Investigational Product', 'hospitalization should 1 be', '2. INVESTIGATE for infection', 'considered', '2. PERFORM biological', 'investigations for infection', 'in both situations', '3. INFORM the local monitor', '4. INVESTIGA TE previous treatments, particularly long-term,', 'even a long time ago, exposure to toxic agents, e.g., benzene,', 'X-rays, etc.', '5. PERFORM and collect the following investigations (results):', 'RBC and platelet counts', 'Serology: EBV, (HIV), mumps, measles, rubella', '6. DECISION for bone marrow aspiration: to be taken in', 'specialized unit', '7. FREEZE serum (5 mL x 2) on Day 1 (cessation of', 'Investigational Product) and Day 5 (For further investigations)', '8. MONITOR the leukocyte count 3 times per week for at least', 'one week, then twice a month until it returns to normal', 'Property of the Sanofi Group - strictly confidential', 'Page 109', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'INCREASE IN ALT', 'ALT > 3 ULN', 'COMPLETE the specific CRF forms for', 'ALT Increase\" and inform the', 'Monitoring Team within 24 hours', 'Confirm ALT > 3 ULN', 'Retest within 72 hours of initial', 'Yes', 'sample*', 'No', 'Total Bilirubin > 2 ULN', 'Continue IMP administration', 'No', 'ALT > 5 ULN (if baseline ALT 2 ULN), or', 'No', 'ALT >8 ULN (if baseline ALT > 2 ULN)', 'Yes', 'Monitor LFTs every 72 hours', 'Yes', 'IMP administration can be continued as', 'long as - under close monitoring -', 'conditions for permanent', 'Permanent Discontinuation of IMP', 'discontinuation or temporary', 'interruption per protocol are not met', 'In ANY CASE, FOLLOW the instructions listed in the box below:', '1. INFORM the Site Monitor who will forward the information to the Study Manager', '2.', 'INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or hypotension and/or episode of', 'arrhythmia in the previous 72 hours; rule out muscular injury', '3. PERFORM the following tests:', '- LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR', '- CPK, serum creatinine, complete blood count', '- Anti-HAV IgM, anti-HBc IgM (HBV-DNA if clinically indicated), anti-HCV and HCV RNA, anti-', 'CMV IgM and anti-HEV IgM antibodies', '- Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma', '- Hepatobiliary ultrasonography (or other imaging investigations if needed)', '4. CONSIDER Auto-antibodies: antinuclear, anti-DNA, anti-smooth muscle, anti-LKM', '5.', 'CONSIDER consulting with hepatologist', '6. CONSIDER patient hospitalisation if INR>2 (or PT<50%) and/or central nervous system disburbances suggesting hepatic', 'encephalopathy', '7. MONITOR LFTs after discontinuation of IMP:', 'As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to normal/baseline or clinical', 'resolution.', '8. FREEZE serum sample (5ml x 2)', '9. In case of SUSPICION of GILBERT Syndrome, a DNA diagnostic test should be done', '*If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation', 'Note:', '\"Baseline\" refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the baseline', 'visit. The algorithm does not apply to the instances of increase in ALT during screening.', 'See Section 10.4 for guidance on safety reporting.', 'Normalization is defined as < ULN or baseline value, if baseline value is >ULN.', 'Property of the Sanofi Group - strictly confidential', 'Page 110', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}